Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Free Cash Flow (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Free Cash Flow for 9 consecutive years, with -$7.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Free Cash Flow fell 48.21% to -$7.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$35.4 million, a 12.7% decrease, with the full-year FY2024 number at -$35.4 million, down 12.7% from a year prior.
  • Free Cash Flow was -$7.2 million for Q4 2024 at SELLAS Life Sciences, up from -$7.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $3.4 million in Q4 2020 to a low of -$12.1 million in Q1 2023.
  • A 5-year average of -$6.4 million and a median of -$6.4 million in 2020 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 181.99% in 2020, then tumbled 245.33% in 2021.
  • SELLAS Life Sciences' Free Cash Flow stood at $3.4 million in 2020, then crashed by 245.33% to -$5.0 million in 2021, then fell by 3.54% to -$5.2 million in 2022, then rose by 6.35% to -$4.8 million in 2023, then tumbled by 48.21% to -$7.2 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Free Cash Flow are -$7.2 million (Q4 2024), -$7.8 million (Q3 2024), and -$9.7 million (Q2 2024).